17 May 2021 - Staying Safe on the Way to Innovative Therapeutic Options - Phase I Trials in Research Clinics

Webinar Topic

Staying Safe on the Way to Innovative Therapeutic Options - Phase I Trials in Research Clinics  


Webinar Date & Time

17 May 2021 from 3:00 PM to 4:30 PM (CEST)

Webinar Overview

In the light of a global pandemic, clinical research in early-stage development reached a new degree of interest as the world relies on scientists to find solutions for unmet medical needs. Under the pressure of this scenario all parties involved in clinical research have to re-organise the working floor and find to ensure the utmost safety of trial participants while in parallel improve the productivity and speed.

In drug development the most sensitive part is the switch from non-clinical to clinical conduct, namely the First-in-Human/First-in-Patient (FIH/FIP) Phase I clinical trials.
To ensure utmost safety a trial specific risk analysis and risk-minimizing measures are required for trial design and protocol as well as for the translation into practical conduct for executing infrastructures in specialized Phase I research clinics.

The basic principles of safety arrangements in clinical trials are regulated by international guidelines and local laws and requirements. For the EU countries the Clinical Trials Regulation 536/2014 based on ICH GCP E6 is implemented as binding law for the conduct of clinical trials.

Since this law does not distinguish between the different phases of drug development starting with FIH/FIP Phase I up to confirmatory Phase III trials, the EMA took action in 2017 to update the guideline for FIH/FIP clinical trials which states that “the early clinical development of human medicinal products has an intrinsic element of uncertainty in relation to both the possible benefits and risks of a novel drug candidate”.

This webinar will help to understand more about the risks and benefits of early-stage clinical trials conducted in specialized Phase I research clinics. It will highlight the points to be considered for planning and conduct of Phase I trials:

  • safety management plan
  • adequate personal resources
  • adequate locations/wards
  • adequate technical equipment
  • processes for management of emergencies
  • adequate conditions for PK sample, collection, handling and processing.



Dr Angela Bischoff

Dr Angela Bischoff

Dr. Angela Bischoff, PhD

Director Clinical Operations
ARENSIA Exploratory Medicine

Dr. Angela Bischoff, PhD has been part of ARENSIA Exploratory Medicine since its foundation and is the Director of Clinical Operations. Over the last 20 years Angela has worked in project management and quality assurance for Phase I/II clinical trials involving both, healthy volunteers and patients. Her experience includes pharmacological and logistic overview of more than 500 early stage development clinical trials.

Dr. Eugenia Prohin

Dr. Eugenia Prohin, MsC
Manager Clinical Operations
ARENSIA Exploratory Medicine

Dr. Eugenia Prohin, psychiatrist by training, has been lead investigator in neuroscience research at ARENSIA Exploratory Medicine since 2012 and Manager International Clinical Operations since 2018. Dr. Prohin was directly involved into the development of corporate strategy of continuous clinical operations during the COVID-19 pandemic. Dr. Prohin performs clinical overview of early phase trials in 7 ARENSIA research clinics in Eastern Europe.

Attendance Fee

€ 90,- for non-EUCROF members

€ 60,- for EUCROF members

Deadline for registration

25 April 2021

How to register?

1) Go on the REGISTRATION PAGE and click on the green "REGISTER" button

2) Check your order and click on the green "CHECKOUT" button

3) Fill in all the necessary information and validate your order


You will receive 2 confirmation emails:

A) One from Eventbrite with your invoice

B) One from "GoToWebinar" with all the necessary information to connect the D-Day!


Should you have any questions about registration, invoices or connection, do not hesitate and contact us by email at This email address is being protected from spambots. You need JavaScript enabled to view it.

By registering to the webinar, you give your authorisation to the webinar organizers to use your email address and personal information to communicate with you about this event and future initiatives. To stop receiving their communications, please contact the organizers directly at This email address is being protected from spambots. You need JavaScript enabled to view it..